Clinical Trials Logo

Rectal Cancer clinical trials

View clinical trials related to Rectal Cancer.

Filter by:

NCT ID: NCT06390982 Not yet recruiting - Rectal Cancer Clinical Trials

Organ Preservation With Tislelizumab and Total Neoadjuvant Therapy in Patients With Low Rectal Cancer: RELIEVE -01 Study

Start date: May 2024
Phase: Phase 2
Study type: Interventional

This is an open-label, multi-center, single-arm clinical study. All patients received concurrent chemoradiation therapy (CRT) followed by 4 cycles of tislelizumab combined with CAPOX, then underwent clinical response assessment. Patients who achieved CR (cCR+ pCR confirmed by local resection of ncCR) continue tislelizumab combined with CAPOX for another 4 cycles and tislelizumab for 9 cycles, then Watch and Wait. Patients who did not achieved CR underwent total mesorectal excision (TME).

NCT ID: NCT06382415 Completed - Rectal Cancer Clinical Trials

Organ/Space Surgical Site Infection and Recurrence and Survival in Rectal Cancer Surgery

VINCat_PDO_2
Start date: January 1, 2011
Phase:
Study type: Observational

In rectal cancer surgery, the organ/space surgical site infection (O/S-SSI) has an impact on patient's prognosis. Its influence in the oncologic outcomes remains controversial. The main objective is to assess the possible effect of O/S-SSI on long-term overall survival and cancer recurrence.

NCT ID: NCT06380855 Recruiting - Rectal Cancer Clinical Trials

Flexible Colonoscope Assisted Hybrid Transanal Total Mesorectal Resection (taTME)

Start date: August 24, 2022
Phase:
Study type: Observational

The investigators propose to use flexible endoscopy combined with transanal total mesorectal resection to further reduce anal injury.

NCT ID: NCT06380101 Recruiting - Rectal Cancer Clinical Trials

Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC)

NEAAR-LARC
Start date: September 8, 2023
Phase: N/A
Study type: Interventional

This clinical study aims to assess feasibility, safety, tolerability, and compliance of a Nonessential Amino Acid Restriction (NEAAR) medical food in adult patients with locally advanced rectal cancer during standard of care short course radiotherapy followed by standard of care chemotherapy.

NCT ID: NCT06376227 Completed - Rectal Cancer Clinical Trials

Robotic-Assisted or Laparoscopic Radical Resection for Rectal Cancer With or Without Left Colic Artery Preservation

Start date: April 1, 2020
Phase:
Study type: Observational

Brief Summary Background The preservation of the left colic artery (LCA) during rectal cancer resection remains a topic of controversy, and there is a notable absence of robust evidence regarding the outcomes associated with LCA preservation. And the advantages of robotic-assisted laparoscopy (RAL) surgery in rectal resection remain uncertain. The objective of this study was to assess the influence of LCA preservation surgery and RAL surgery on intraoperative and postoperative complications of rectal cancer resection. Methods Participants who underwent laparoscopic (LSC) or RAL with or without LCA preservation resection for rectal cancer between April 2020 and May 2023 were retrospectively assessed. The patients were categorized into two groups: low ligation (LL) which with preservation of LCA and high ligation (HL) which without preservation of LCA. A one-to-one propensity score-matched analysis was performed to decrease confounding. The primary outcome was operative findings, operative morbidity, and postoperative genitourinary function.

NCT ID: NCT06369597 Not yet recruiting - Rectal Cancer Clinical Trials

A Randomized Controlled Trial of the Safety and Efficacy of Robotic Telesurgery Versus Laparoscopic Surgery

Start date: April 15, 2024
Phase: N/A
Study type: Interventional

This is a randomized controlled trial that will be preceded by a safety trial focusing on the safety and efficacy of robotic telesurgery. The hypothesis is that robotic telesurgery has a non-inferior primary endpoint event rate to local laparoscopic surgery.

NCT ID: NCT06366841 Recruiting - Rectal Cancer Clinical Trials

Stigma and Psychological profilE in REctal-anal caNcer pAtients

SERENA
Start date: May 6, 2024
Phase:
Study type: Observational

In 2022, Italy is estimated to have 48,100 cases of colon-rectum cancer. Locally advanced mid-lower rectal cancers require preoperative chemo-radiotherapy with fluoropyrimidine. The diagnosis and treatment of rectal cancer have a significant impact on patients' well-being, causing physical and psychological distress. Symptoms such as abdominal pain, fatigue, diarrhea, are commonly reported. While distress levels have been examined before, the relationship between other aspects of the patient experience, such as psychosocial factors, stigma, temperament and personality, alexithymia, have not been extensively explored. Colorectal cancer is associated with specific socially stigmatized challenges. Stigmatization is defined as societal identification of an individual as abnormal and worthy of separation, leading to discrimination and loss of social status. Rectal cancer patients may perceive high levels of stigma and blame due to factors such as defecation-related symptoms, colonoscopy or rectal examinations, physical limitations, loss of work ability and the use of colostomy or ileostomy. Anal cancer, although traditionally surrounded by social stigma, is gaining awareness worldwide due to increasing diagnoses. In other forms of cancer, stigma has been linked to personality traits. Given the characteristics related to the illness and the profile of rectal and anal cancer patients, it is important to assess the psychological traits and psychological resources, also in order to establish tailored psychological pathways during the disease trajectory that comprehend chemoradiations and possible subsequent surgery. Currently, there is no documented data on the relationship between stigma, and psychological profiles in rectal and anal cancer patients. Aim of this protocol is to evaluate the stigma, and psychopathological profile in rectal and anal cancer patients and to evaluate changes in those variables over time.

NCT ID: NCT06340646 Recruiting - Multiple Myeloma Clinical Trials

Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)

Start date: October 18, 2022
Phase: N/A
Study type: Interventional

The overall goal of the WU-PE-CGS is to build a rigorous, scientific evidence base for approaches that direct engagement of cancer patients and post-treatment cancer survivors as participants in cancer research, and to investigate the impact of directly engaging participants in decisions regarding returning of genomic results on participants' health and satisfaction. Participants in this study will be presented with the choice of types of genomic results to receive, and the Engagement Optimization Unit (EOU) will investigate the impact of this intervention on participant knowledge, expectations of benefit, personal utility, and decisional conflict.

NCT ID: NCT06337552 Recruiting - Rectal Cancer Clinical Trials

High-Fermented Food Intervention Among Locally Advanced Rectal Cancer Patients (The FEED Trial)

Start date: February 19, 2024
Phase: N/A
Study type: Interventional

The purpose of the study is to evaluate the feasibility and acceptability of a dietary intervention (FEED-FF) that includes fermented foods (FF), among locally advanced rectal cancer patients, and to explore whether this diet can improve outcomes in rectal cancer patients receiving chemoradiotherapy (CRT).

NCT ID: NCT06328361 Recruiting - Rectal Cancer Clinical Trials

Nordic ORgan Preservation Pilot Approach Nonrandomised Single-Arm Trial for Non-Operative Management of Rectal Cancer

NORPPA-1
Start date: May 16, 2024
Phase: N/A
Study type: Interventional

The goal of this one-arm clinical trial is to implement and study the oncological outcomes of nonoperative management of rectal cancer having complete clinical response to neoadjuvant therapy. The main questions to answer are - if the oncological results of nonoperative management after Nordic practice in chemoradiotherapy indications differ from experiences elsewhere - what is the organ preservation rate - what is the local regrowth rate